**Supplementary table. Predictive factors of humoral response after COVID-19 in univariate analysis**

|  |  |
| --- | --- |
| Variable | IgG index (n=61) |
| IgG index, mean±SD | Correlation coefficient (95% CI) | p-value |
| Age |  | 0.0358 (-0.218; 0.285) | 0.78\* |
| Sex |  |  | 0.61† |
| Women | 46.4±46.0 |  |  |
| Men | 56.1±79.1 |  |  |
| EDSS score |  | 0.0919 (-0.164; 0.336) | 0.48\* |
| COVID-19 related comorbidities |  |  | 0.99† |
| Yes | 54.4±67.5 |  |  |
| No | 48.7±57.4 |  |  |
| Disease-modifying treatment group |  |  | **0.03‡** |
| No treatment | 64.4±63.1 |  |  |
| No risk | 71.6±66.8 |  |  |
| Low risk | 56.3±61.9 |  |  |
| Moderate to high risk | 13.2±20.5 |  |  |
| COVID-19 severity score |  |  | **0.02†** |
| Grade 1-2 | 43.1±52.6 |  |  |
| Grade ≥3 | 109±80.3 |  |  |
| PCR result |  |  | **0.14†** |
| Positive | 61.4±67.1 |  |  |
| Not performed | 32.6±38.4 |  |  |
| Time between COVID-19 onset and serology |  | -0.296 (-0.510; -0.0477) | **0.02**\* |
| Time between COVID-19 onset and serology |  |  | **<0.01†** |
| ≤168 days | 68.9±65.1 |  |  |
| >168 days | 29.7±43.3 |  |  |

*Abbreviations. COVID-19: coronavirus disease 2019. EDSS: Expanded Disability Status Scale.*

\* Pearson correlation coefficient r.

† Mann-Whitney test.

‡ Kruskal-Wallis test.

**Supplementary figure.** **Anti-SARS-CoV-2 IgG index according to time and disease-modifying treatments in patients with repeated serologies**

